1Mielcarek M,Sanmaier BM,Maloney DG,et al.Nonmyeloablative hematopoietic cell transplantation:status quo and future perspectives[J]. J Clin Immunol,2002,22:70-74.
2Kal.wak K ,Ussowicz M, Gorczynska E, et al. Immunologic effects of intermediate-dose IL-2 i.v. after autologous hematopoiectic cell transplantation in pediatric solid tumors[J]. J Interferon cytokine Res,2003, 23(4):173-181.
3MiuraY,Thoburn CJ,Bright EC,et al. Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD):evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD[J].Blood,2001,98:868-876.
4Klingemann HG.Cellular therapy of cancer with natural killer cells:will it ever work[J]? J Hematother Stem Cell Res,2001,10:23-26.
5Chiorean EG,Miller JS.The biology of natural killer cells and implications for therapy of human disease[J]. J Hematother Stem Cell Res,2001,10:451-463.
6Iontagna D, Iaccario R, lontini E,et al. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukemia or myelodysplastic cells using both HLA-matched and partially matched donors[J]. Exp Hematol, 2003,31(11):1031-1038.
7Alvarnas JC,Linn YC,Hope EG,et al.Expansion of cytotoxic CD3+CD+56cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation[J]. Biol Blood Marrow Transplant,2001,7:216-222.
8Verneris MR,Baker J,Edinger M,et al.Studies of ex vivo activated and expanded CD8 NK-T cells in humans and mice[J]. I Clin Immunol,2002,22:131-136.
9Marijt WAF, Falkenburg JHF.Specific T cell therapy in leukemia[J]. J Hematother Stem Cell Res, 2001,10:493-500.
10Gottschalk S,Ng CYC,Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs [J]. Blood,2001,94:835-842.
